Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

4.07 Questions from a Medical Student with Emma Greenstreet and Dr. Vinay Prasad

We have a reverse episode for you today! Emma Greenstreet, a second-year medical student at UCSF, interviews our usual host, Dr. Vinay Prasad on why and how he chose hematology/oncology as a specialty, engaging with criticism, mentorship, medical student rotations, choosing a research project, and urging doctors in academia to aim higher.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul Banerjee

We sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

4.05 Exodus from Academia and the Regretful FDA Approval of Aducanumab with Dr. Ameet Sarpatwari

Today we are joined by Dr. Ameet Sarpatwari of Harvard Medical School to discuss how so many great minds in oncology are leaving cancer research in academia for industry. We also talk about the evidence (or lack thereof) behind the recent FDA approval of aducanumab to treat Alzheimer's disease.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

4.04 Treatment Algorithm for Follicular Lymphoma & Assessing RCTs

Today we have a short monologue for you on just a few topics: a treatment algorithm for follicular lymphoma and our host Dr. Prasad's new paper out now in the European Journal of Clinical Investigation: "Reliable, cheap, fast and few: What is the best study for assessing medical practices? Randomized controlled trials or synthetic control arms?”

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

4.03 Multiple Myeloma, Productivity Metrics, and Field Changes in Oncology with Dr. Nina Shah

Today we're back with another real-life (non-virtual!) interview. We're joined by Dr. Nina Shah of UCSF to discuss her career and her work in mutiple myeloma as well as the complexities of advancing your career -- dealing with productivity metrics like the h-index or the Kardashian index, switching institutions, balancing work with your home life, adapting to the changing field of oncology, and more.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.90 Redesigning Health Care, Overuse, Burnout, and COVID-19 Groupthink with Dr. Marty Makary

On today's episode, we interview Dr. Marty Makary of Johns Hopkins School of Medicine and Bloomberg School of Public Health on how he chose his path in medicine, how health care as it is in the United States needs to change, and how groupthink dominated COVID-19 health policy. We discuss a variety of topics from his research on overuse, the prevalence of burnout in healthcare professionals, silos in medicine, to patients' lawsuits against hospitals. We touch on his two books, the latter of which has a new edition coming out next month that addresses COVID-19: Unaccountable: What Hospitals Won't Tell You and How Transparency Can Revolutionize Health Care, and "The Price We Pay: What Broke American Health Care--and How to Fix It".

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.88 Behind the Scenes for the One-Year Anniversary of Malignant with Dr. Vinay Prasad

Today's episode is hosted by guest Logan Powell, an incoming medical student at the Texas A&M College of Medicine and creator of this podcast's show notes. He reverse interviews our usual host, Dr. Vinay Prasad, in honor of the one-year anniversary release of Dr. Prasad's book "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer". They explore a few behind-the-scenes stories.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.87 Round Table on Multiple Myeloma Initial Therapy, High Risk, and Maintenance

Today we try something new. We're joined by five esteemed multiple myeloma experts for a back-and-forth round table discussion on the disease, including initial therapy, high risk, and maintenance. Our guests are Dr. Raj Chakraborty of Columbia University, Dr. Sam Rubinstein of the University of North Carolina Chapel Hill, Dr. Manni Mohyuddin of the University of Utah, Dr. Ben Derman of the University of Chicago, and Dr. Kevin Knopf of Highland Hospital.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.86 Lenvatinib plus Pembrolizumab or Everolimus for Advanced RCC with Dr. Karine Tawagi

Today we bring back our popular Journal Club with a Fellow segment. We're joined by Dr. Karine Tawagi of the Oschner Clinic in Louisiana to discuss the CLEAR trial: "Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma" as published in the New England Journal of Medicine.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.85 Med-Psych, Palliative Care, and Respect for Autonomy and Dignity with Dr. Joshua Briscoe

Our guest today is Dr. Joshua Briscoe of Duke University. We discuss Med-Psych (a joint internal medicine and psychiatry residency) and how it and palliative care connect to the human side to medicine: providing the care for quality of life and dignity that patients actually need, from comfortable bedding to physician-assisted suicide.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.83 MetaResearch, Reproducibility, Expertise, & Early Career Researchers with Dr. Ioana Cristea

Today we sit down with Dr. Ioana Cristea of the University of Pavia, Italy and the Meta-Research Innovation Center at Stanford to discuss meta-research, reproducibility, and expertise. We also talk about our shared experiences as "early career researchers" (ECRs), also known as Early Stage Investigators, a term coined by the National Institutes of Health to describe researchers who earned their last research degree less than 10 years ago.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.82 Classical Hematology Chat on CVT and VITT with Drs. Sven Olson and Joseph Shatzel

Today we host a Classical Hematology Chat on thrombosis associated with COVID-19 vaccines. We're joined by Drs. Sven Olson and Joseph Shatzel of Oregon Health & Science University as we talk about cerebral venous thrombosis (CVT) and vaccine-induced immune thrombotic thrombocytopenia (VITT).

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.80 ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) with Drs. Bishal Gyawali and Nathan Cherny

Today we sit down with Dr. Bishal Gyawali of Queen's University in Kingston, Ontario, Canada and with Dr. Nathan Cherny of Shaare Zedek Medical Center in Jerusalem, Israel to talk about the European Society of Medical Oncology (ESMO) and the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), which aims to improve cancer therapy decision-making.

Read More
Oncology, Medicine, Health Policy Kerrington . Oncology, Medicine, Health Policy Kerrington .

3.79 Sweden's Stance on COVID-19, Hydroxychloroquine, Schools, & Mask Data with Dr. Cathrine Axfors

On today's episode, we sit down with Dr. Cathrine Axfors of the Meta-Research Innovation Center at Stanford (METRICS) to discuss how Sweden responded to COVID-19 and the nation's attention to what policies would be sustainable. We also touch on her paper "Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials" as well as school closures, data to support mask policies, and more!

Read More